METASTATIC COLORECTAL CANCER

This study tested whether a new drug called A140 works as well as the standard drug Erbitux for people with a certain type of advanced colorectal cancer (RAS wild-type). Both drugs were given together with chemotherapy. The trial involved 688 adults who had not received chemother…

This study tested an experimental drug called CTX-009 in 49 adults with metastatic colorectal cancer that had worsened after two or three prior treatments. The goal was to see if the drug could shrink tumors or stop them from growing. While not a cure, it aims to give patients mo…

This early-phase study tested the safety and best dose of two drugs—regorafenib and nivolumab—given together to people with advanced colorectal cancer that has not responded to standard treatments. The cancer type studied is mismatch repair proficient, meaning it does not have a …

This study allowed people with certain cancers (ovarian, basal cell, or colorectal) who had already shown benefit from the drug vismodegib in earlier trials to keep receiving it. The main goal was to track safety and side effects over time. Only 19 patients took part, all of whom…

This early-phase study tested a combination of two treatments—regorafenib and FOLFIRINOX chemotherapy—in 13 people with advanced colorectal cancer that has a specific gene change (RAS mutation). The main goal was to see if the combination is safe and tolerable. Researchers also l…

This study tested whether adding the drug pembrolizumab to standard radiation or ablation could help the immune system attack tumors that were not directly treated. It included 34 people with metastatic colorectal cancer who had already tried at least two standard treatments. The…

This study tested whether adding the targeted drug panitumumab to a special chemotherapy given directly into the liver (hepatic arterial infusion) plus standard IV chemo could help keep colorectal cancer from coming back after liver metastases were surgically removed. 75 adults w…

This study tested a new drug called ERAS-007 combined with other cancer treatments in 101 people with advanced colorectal or pancreatic cancer that had spread. The main goals were to find safe doses and check for side effects. Researchers also looked at whether the drug combo cou…

This early-phase study tested a new antibody drug (anti-EGFr) in 18 people with advanced colorectal cancer that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received the drug weekly until their diseas…

This study tested a new two-drug combination (encorafenib plus cetuximab) against standard treatments in 107 Chinese patients with a specific genetic mutation (BRAF V600E) causing metastatic colorectal cancer. The goal was to see if the new combo could slow cancer growth better t…

This study tested combinations of a drug called etrumadenant (AB928) with other treatments in 227 adults whose colorectal cancer had spread. The goal was to see if these combos could shrink tumors or slow cancer growth, and to check for side effects. Participants had to be in fai…

This early-phase study tested a maintenance treatment for people with a specific type of advanced colorectal cancer (KRAS/BRAF wild-type). The treatment combined two drugs, cetuximab and capecitabine, given every three weeks. The main goals were to check safety and how the drug m…

This study tested a combination of two drugs, sorafenib and irinotecan, in 64 adults with advanced colorectal cancer that had a specific gene change called K-RAS. The goal was to see if the combination could control the cancer after other treatments had stopped working. The study…

This study tested a new immunotherapy called STIMVAX in 29 adults with metastatic colorectal cancer that had not responded to two prior treatments. The therapy uses immune cells from healthy donors to help the body fight cancer. Researchers measured how long patients lived and ch…

This study looked back at medical records of 274 people with a specific genetic mutation (BRAF V600E) in advanced colorectal cancer. The goal was to see which treatments doctors actually used and how well they worked in everyday practice. No new treatments were tested; instead, r…

This study looked at the order in which people with advanced bowel cancer (metastatic colorectal cancer) received two approved treatments: regorafenib and TAS (with or without bevacizumab). Researchers collected data from 121 patients in Europe to see how long each treatment sequ…

This study tested whether special sensors could measure changes in urine chemicals to monitor how well chemotherapy is working in people with metastatic colorectal cancer. Sixteen participants provided daily urine samples before and after starting chemotherapy. The goal was to se…

This study looked at whether measuring natural chemicals in urine over 2 days could help monitor cancer therapy. Researchers collected 10 urine samples from 32 people with metastatic colorectal cancer and compared them to healthy volunteers. The goal was to see if daily patterns …

This study looked at 74 people with metastatic colorectal cancer starting their first chemotherapy. Researchers checked if early changes in blood markers (like CEA and tumor DNA) could predict whether the cancer would shrink after 3 months. The goal is to see if blood tests can h…

This study looked at how long people with advanced colorectal cancer lived after taking regorafenib, a drug given when other treatments stop working. Researchers followed 704 patients in France who received the drug through a special access program. The goal was to see real-world…